Dinesh Patel
Vermögen: 52 Mio $ am 31.05.2026
Vermögen: 52 Mio $ am 31.05.2026
Dinesh V.
Patel was the founder of Miikana Therapeutics, Inc., founded in 2003, where the title held was President & Chief Executive Officer from 2003 to 2005.
Current jobs include President, Chief Executive Officer & Director at Protagonist Pty Ltd. since 2013, President, Chief Executive Officer & Director at Protagonist Therapeutics, Inc. since 2019, and Independent Director at Sai Life Sciences Ltd. starting in 2025.
Former jobs include President & Chief Executive Officer at Arête Therapeutics, Inc. from 2006 to 2008, Chemistry Director at Affymax, Inc. from 1993 to 1996, Medicinal Chemist at Bristol Myers Squibb Co. from 1985 to 1993, and Senior Vice President-Licensing & Drug Discovery at Vicuron Pharmaceuticals LLC from 1996 to 2003.
Education includes a doctorate from Rutgers State University of New Jersey and an undergraduate degree from Sardar Patel University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.05.2026 | 523’478 ( 0.81% ) | 52 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.12.2008 |
| SAI LIFE SCIENCES LIMITED | Direktor/Vorstandsmitglied | 24.03.2025 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Vorstandsvorsitzender | 06.07.2009 |
| Unternehmen | Position | Ende |
|---|---|---|
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops and commercializes molecule drugs to treat cardiovascular diseases | Vorstandsvorsitzender | 01.01.2008 |
Miikana Therapeutics, Inc.
Miikana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of cancer and inflammatory diseases | Vorstandsvorsitzender | 01.01.2005 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01.01.2003 |
| AFFYMAX, INC. | Corporate Officer/Principal | 01.01.1996 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1993 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Miikana Therapeutics, Inc.
Miikana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of cancer and inflammatory diseases | Health Technology |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops and commercializes molecule drugs to treat cardiovascular diseases | Health Technology |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Health Technology |
Affymax, Inc.
Affymax, Inc. BiotechnologyHealth Technology Develops and distributes pharmaceutical products | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sardar Patel University
Sardar Patel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sai Life Sciences Ltd.
Sai Life Sciences Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in contract research and manufacturing activities for pharmaceutical & biotechnology industries | Commercial Services |
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures peptide based therapeutic products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen